Overview: Oncologic, Endocrine & Metabolic Antisense oligonucleotides for the treatment of cancer

References

• ZAMECNIK P, STEPHENSON M: Inhibition of Rous sarco-ma virus replication and cell transformation by a spe-cific oliqodeoxynucleotides. Proc. Natl. Acad. Sci. USA (1978) 75:280–284.
   PubMed Web of Science ®Google Scholar
• MIZUNO T, CHOU MY, INOUYE M: A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA). Proc. Natl. Acad. Sci. USA (1984) 81:1966–1970.
   PubMed Web of Science ®Google Scholar
• HEYWOOD SM: tcRNA as a naturally occurring antisense RNA in eukaryotes. Nucl. Acids Res. (1986) 14:6771–6772.
   PubMed Web of Science ®Google Scholar
• PATERSON BM, ROBERTS BE, KUFF EL: Structural gene Identification and mapping by DNA. mRNA hybrid-ar-rested cell-free translation. Proc. Natl. Acad. Sci. USA (1977) 74:4370–4374.
   PubMed Web of Science ®Google Scholar
• WICKSTROM EL, BACON TA, GONZALEZ A, LYMEN GH, WICKSTROM E: Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are Inhibited by an antisense pentadeadeoxynudeoticle. Proc. Natl. Acad. Sci. USA (1988) 85:1028–1032.
   PubMed Web of Science ®Google Scholar
• HOLT JT, REDNER RL, NIENHUIS AW: An oligomer com-plementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol. Cell. Biol. (1988) 8:963–973.
   PubMed Web of Science ®Google Scholar
• BACON TA, WICKSTROM E: Daily addition of an anti-c-myc DNA oligomer induces granulocytic differentiation of human promyelocytic leukemia 1IL-60 cells in both serum-containing and serum-free media. Oncogene Res. (1991) 6:21–32.
   PubMedGoogle Scholar
• BACON TA, WICKSTROM E: Walking along human c-myc mRNA with antisense oligonucleotides: Maximum effi-cacy at the 5' cap region. Oncogene Res. (1991) 66:13–19.
   Google Scholar
• WICKSTROM E, BACON TA, WICKSTROM EL: Down-regu-lation of c-MYC antigen expression in lymphocytes of E-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res. (1992) 52:6741–6745.
   PubMed Web of Science ®Google Scholar
• ROSOLEN A, WHITESELL L, IKEGAKI N, KENNETT RH, NECKERS LM: Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line. Cancer Res. (1990) 50:6316–6322.
   PubMedGoogle Scholar
• WHITESELL L, ROSOLEN A, NECKERS LM: In vivo modula-tion of N-myc expression by continuous perfusion with an antisense oligonudeotide. Antiserzse Res. Dev. (1991) 1(4):343–350.
   PubMedGoogle Scholar
• MOSCOVICI C, GAZZOLO L: Transformation of hemopoietic cells and avian leukemia viruses. In: Ad-vances in Viral Oncology, Oncogene Studies, Klein G (Ed), Raven Press, NY, (1982) Vol. 1, pp. 83106.
   Google Scholar
• ANFOSSI F, GEWIRTZ AM, CALABRETTA B: An oligomer complementary to c-myb encoded mRNA inhibits pro-liferation of human myeloid leukemia cell lines. Proc. Natl. Acad. Sci. USA (1989) 86:3379–3383.
   PubMed Web of Science ®Google Scholar
• CALABRETTA B, SIMS RB, VALiititI M, CARACCIOLO D, SZCYIIK C, VENTUREELLI D, RATAJCZAK M, BERAN M, GEWIRTZ AM: Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antbense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc. Natl. Acad. Sci. USA (1991) 88:2351–2355.
   PubMed Web of Science ®Google Scholar
• RATAJCZAK MZ, ICANT JA, LUGER SM, HIJIYA N, ZI-IANG J, ZON G, GEWIRTZ AM: In vivo treatment of human leukemia in a acid mouse model with c-myb antisense oligodeoxynudeotides. Proc. Natl. Acad. Sci. USA (1992) 89:11823–11827.
   PubMed Web of Science ®Google Scholar
• ARSURA M, INTRONA M, PASSERINI F, MANTOVANI A, GOLAY J: B-myb antisense oligonucleotides inhibit pro-liferation of human hematopoietic cell lines. Blood (1992) 79(10):2708–2716.
   PubMedGoogle Scholar
• HEISTERKAMP N, STEPHENSON JR, GROFFEN J, HANSEN PF, DE KLEIN A, BARTRAM CR, GROSVELD G: Localisation of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature (1983) 306:239–242.
   PubMed Web of Science ®Google Scholar
• SHTIVELMAN E, LIFSHTTZ B, GALE RB, ROE BA, CANAANI E: Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell (1986) 47:277–284.
   PubMed Web of Science ®Google Scholar
• FAINSTEIN E, MARCELLE C, ROSNER A, CANAANI E, GALE RP, DREAZEN O, SMITH SD, CROCE CM: A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature (1987) 330:386–391.
   PubMed Web of Science ®Google Scholar
• DALEY GQ, VAN ETTEN RA, BALTIMORE D: Induction of chronic myelogenous leukemia in mice by the P210bce/abl gene of the Philadelphia chromosome. Sci-ence (1990) 247:824–836.
   PubMed Web of Science ®Google Scholar
• HEISTERKAMP N, JENSTER G, TEN HOEVE J, ZOVICH D, PATTENGALE PK, GROFFEN J: Acute leukaemia in bcr/abl transgenic mice. Nature (1990) 344:251–254.
   PubMed Web of Science ®Google Scholar
• KELLIHER MA, MCLAUGHLIN J, WITTE ON, ROSENBERG N: Induction of a chronic myelogenous leukemia-like syn-drome in mice with v-abl and BCR/ABL Proc. Natl. Acad. Sci. USA (1990) 87:6649–6653.
   PubMed Web of Science ®Google Scholar
• ELEFANTY AG, HARIHARAN IK, CORY 5: bcrabl, the hallmark of chronic myeloid leukaemia in man, in-duces multiple haematopoietic neoplasms in mice. EMBO J. (1990) 9(4):1069–1078.
   PubMedGoogle Scholar
• SZCZYLIK C, SKORSKI T, NICOLAIDES NC, MANZELLA L, MALAGUARNERA L, VENTURELLI D, GEWIRTZ AM, CALABRETTA B: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynu-cleoticies. Science (1991) 253:11–27.
   Google Scholar
• KAMEL-REID S, LETARTE M, SIRARD C, DOEDENS M, GRUNBERGER T, FULOP G, FREEDMAN MH, PHILLIPS RA, DICK JE: A model of human acute lymphoblastic leuke-mia in immune-deficient SCID mice. Science (1989) 246:1597–1600.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, TENSANABU J, TANG JY: Pharmacokine- tics biodistribution and stability of oligodeoxynu-cleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA (1991) 88:7595–7599.
   PubMed Web of Science ®Google Scholar
• CALABREITA B, SKORSKI T, ZON G: Antisense oligonuc- leotides. Sem. Cancer Biol. (1992) 3:391-398.Thorough review.
   Google Scholar
• SAISON-BEHMOARAS T, TOCQUE B, REY I, CHASSIGN- OL M, THUONG NT, HÉLÈNE C: Short modified antisense oligonucleotides directed against Ha-ras point mutation Induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J. (1991) 10:1111–1118.
   PubMed Web of Science ®Google Scholar
• KOIZUMI M, HAYASE Y, IWAI S, KAMIYA H, INOUE H, OHTSUKA E: Design of RNA enzymes distinguishing a single base mutation in RNA. Nucleic Acids Res. (1989) 17:7059–7071.
   PubMed Web of Science ®Google Scholar
• GRAY GD, HERNANDEZ OM, HEBEI D, ROOT M, POW- SANG JM, WICKSTROM E: Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res. (1993) 53:577–580.
   PubMed Web of Science ®Google Scholar
• FEARON ER, VOGELSTEIN B: A genetic model for colorec-tal tumorigenesis. Cell (1990) 61:759–767.
   PubMed Web of Science ®Google Scholar
• DALLA-FAVERA R, MARTINOTTI S, GALLO RC, ERIKSON J, CROCE CM: Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B cell lymphomas. Science (1983) 219:963–967.
   PubMed Web of Science ®Google Scholar
• COLLINS S, GROUDINE M: Amplification of endogenous myc-related DNA sequences in a human myeloid leuke-mia cell line. Nature (1982) 299:679–681.
   Google Scholar
• MURRAY MJ, CUNNINGHAM JM, PARADA LF, DAUTRY F,LEBOWIRTZ P, WEINBERG RA: The HL-60 transforming sequence: a ras oncogene coexisting with altered myc genes in hematopoietic tumors. Cell (1983) 33:749–757.
   PubMed Web of Science ®Google Scholar
• BAKER SJ, MARKOWITZ S, FEARON ER, \WILLSON JKV,VOGELSTEIN B: Suppression of human colorectal carci-noma cell growth by wild-type p53. Science (1990) 249:912–915.
   PubMed Web of Science ®Google Scholar
• BIRCHNELL-ROBERTS MC, FERRER C, FERRIS D, FALK LA, KASPER J, WHITE G, RUSCETTI FW: Inhibition of murine monocyte proliferation by a colony-stimulating factor-1 antisense oligodeoxynucleotide. Evidence for autocrine regulation. J. Immunol. (1990) 145:3290–3296.
   Google Scholar
• WU J, ZHU JQ, HAN KK, ZHU DX: The role of the c-fms oncogene in the regulation of HL-60 cell differentiation. Oncogene (1990) 5:873–877.
   PubMed Web of Science ®Google Scholar
• SCHWAB G, SEGALL CB, AARDEN LA, NECKERS L, NOR-DAN RP: Characterisation of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line U266. Blood (1991) 77:587–593.
   PubMed Web of Science ®Google Scholar
• HAREL-BELLAN A, DURUM S, MUEGGE K, ABBAS A, FAR-RAR W: Specific inhibition of lymphokine biosynthesis and autocrine growth using antisense oligonucleotkies In Thl and Th2 helper T cell clones. J. Esp. Med. (1988) 168:2309–2318.
   Google Scholar
• GOSPODAROWICZ D, FERRARA N, SCHWEIGERER L, NEUFELD G: Structural characterisation and biological functions of fibroblast growth factor. Endocr Rev. (1987) 8:95–114.
   PubMed Web of Science ®Google Scholar
• SHING Y, FOLKMAN J, SULLIVAN R, BUTTERFIELD C, MURRAY J, KLAGSBRUN M: Heparin affinity: Purification of a tumor-derived capillary endothelial cell growth factor. Science (1984) 223:1296–1299.
   PubMed Web of Science ®Google Scholar
• JAYE M, HOWK R, BURGESS W, RICCA G, CHILI I, RAVERA M, O'BRIEN S, MODI W, MACIAG T, DROHAN W: Human endothelial cell growth factor: cloning, nucleotide se-quence, and chromosome localisation. Science (1986) 233:541–545.
   PubMed Web of Science ®Google Scholar
• ABRAHAM JA, WHANG JL, TUMOLO A, MERGIA A, FRIED-MAN J, GOSPODAROWICZ D, FIDDES JC: Human basic fibroblast growth factor: nucleotide sequence and genomic organization. EMBO J. (1986) 5:2523–2528.
   PubMed Web of Science ®Google Scholar
• DICKSON C, ACLAND P, SMITH R, DEED R, MACALLAN D, WALTHER W, FULLERPACE F, KIEFER P, PETERS G: Char-acterization of int-2-a member of the fibroblast growth factor family. J. Cell Sci. (1990) 13:87–96.
   Google Scholar
• MIYAGAWA K, SAKAMOTO H, YOSHIDA T, YANASHITA Y, MITSUI Y, FURUSAWA M, MAEDA S, TAKAKU F, SUGIMURA T, TERADA M: bat-1 transforming protein: expression in silkworm cells and characterisation as a novel heparin-binding growth factor. Oncogene (1988) 3:383–389.
   PubMed Web of Science ®Google Scholar
• ZHAN X, BATES B, HU X, GOLDFARB M: The human FGF-5oncogene encodes a novel protein related to fibroblast growth factors. Mol. Cell. Biol. (1988) 8:3487–3495.
   PubMed Web of Science ®Google Scholar
• PIZETTE S, BATOZ M, PRATS H, BIRNBAUM D, COULTERF: Production and functional characterization of hu-man recombinant FGF-6 protein. Cell Growth Differ. (1991) 2:561–566.
   PubMedGoogle Scholar
• FINCH P, RUBIN J, MIKI T, RON D, A.ARONSON S: HumanKGF is FGF-related with properties of a paracrine effec-tor of epithelial cell growth. Science (1989) 245:752–755.
   Google Scholar
• GOLDFARB M: The fibroblast growth factor family. CellGrowth Differ. (1990) 1:439–445.
   Google Scholar
• BURGESS WH, MACIAG T: The heparin-binding (fi-broblast) growth factor family of proteins. Annu. Rev. Biochem. (1989) 58:575–606.
   PubMed Web of Science ®Google Scholar
• RODECK U, HERLYN M, MENSSEN HD, FURLANETTO RW, Koprowski H: Metastatic but not primary melanoma cell lines grow its vitro independently of exogenous growth factors. Int.J. Cancer (1987) 40:687–690.
   PubMedGoogle Scholar
• HALABAN R, GHOSH S, BAIRD A: bFGF is the putative natural growth factor for human melanocytes. In Vitro Cell. Dev. Biol. (1987) 23:47–52.
   PubMed Web of Science ®Google Scholar
• BECKER D, MEIER CB, HERLYN M: Proliferation of human malignant melanomas is inhibited by antisense oli-godeoxynucleotides targeted against basic fibroblast growth factor. EMBO J. (1989) 8(12):3685–3691.
   PubMedGoogle Scholar
• MURPHY PR, SATO Y, KNEE RS: Phophorothioate antis-ense oligonucleotides against basic fibroblast growth factor inhibit anchorage-dependent and anchorage-in-dependent growth of a malignant glioblastoma cell line. Mol. Endocr. (1992) 6:877–884.
   PubMedGoogle Scholar
• KUO JF, GREENGARD P: Cyclic nucleotide-dependent protein kinases. IV. Widespread occurrence of adeno-sine 3,5-monophosphate-dependent protein kinase in various tissues and phyla of the animal kingdom. Proc. Natl. Acad. Sci. USA (1969) 64:1349–1355.
   Google Scholar
• KREBS EG: Protein kinase. Curr. Top. Cell. Regul. (1972) 5:99–133.
   PubMedGoogle Scholar
• BRAMSON HN, KAISER ET, MILDVAN AS: Mechanistic studies of cAMP-dependent protein kinase actions. CRC Grit. Rev. Biochem. (1983) 15:93–124.
   Google Scholar
• BEEBE SJ, CORBIN JD: Cyclic nucleotide-dependent pro-tein kinases. In: The Enzymes: Control by Phospbotylation, Part A (1986). Boyer PD, Kerbes EG (Eds), Academic Press, NY Vol. 17, pp. 43–111.
   Google Scholar
• KREBS EG, BEAVO JA: Phosphorylation-dephosphoryla-tion of enzymes. A. Rev. Biocbem. (1979) 48:923–939.
   PubMed Web of Science ®Google Scholar
• MCKNIGHT GS, CLEGG CH, UHLER MD, CHRD/IA JC, CADD GG, CORRELL LA, OTTEN AD: Analysis of the cAMP-de-pendent protein kinase system using molecular genetic approaches. Recent Prog. Horm. Res. (1988) 44:307–335.
   PubMedGoogle Scholar
• SHOWERS MO, MAURER RA: A cloned bovine cDNA encodes an alternate form of the catalytic subunit of cAMP-dependent protein kinase. J. Biol. Chem. (1986) 261:16288–16291.
   PubMedGoogle Scholar
• BEEBE SJ, OYEN O, SANDBERG M, FROYSA A, HANSSON V, JAHNSEN T: Molecular cloning of a unique tissue-spe-cific protein kinase (y) from human testis-representing a third isoform for the catalytic subunit of the cAMP-de-pendent protein kinase. Molec. Endocr. (1990) 4:465–475.
   PubMed Web of Science ®Google Scholar
• LOHMANN SM, WALTER U: Regulation of the cellular and subcellular concentrations and distribution of cyclic nucleotide- dependent protein kinases. In: Advances in Cyclic Nucleotide and Protein Phospbotylation Research (1984). Greengard P, Robison GA (Eds), Raven Press, NY Vol. 18, pp. 63–117.
   Google Scholar
• CHO-CHUNG YS: Perspectives in Cancer Research: Role of cyclic AMP receptor proteins in growth, differentia-tion, and suppression of malignancy: New approaches to therapy. Cancer Res. (1990) 50:7093–7100.
   PubMed Web of Science ®Google Scholar
• TORTORA G, PEPE S, YOKOZAK1 H, MEISSNER S, CHO-CHUNG YS: Cooperative effect of 8-C1-cAMP and rhGM- CSF on the differentiation of HL-60 human leukemia cells. Biocbem. Biopbys. Res. Comm. (1991) 177:1133–1140.
   PubMed Web of Science ®Google Scholar
• TORTORA G, CIARDIELLO F, ALLY S, CLAIR T, SALOMONDS, CHO-CHUNG YS: Site-selective 8-chkoroadenosine 3±,5±-cyclic monophosphate inhibits transformation and transforming growth factor a production in Ki-ras-transformed rat fibroblasts. FESS Lett. (1989) 242:363–367.
   PubMed Web of Science ®Google Scholar
• BYUS CV, KUMPEL GR, LUCAS DO, RUSSELL DH: Type Iand type 11 cyclic AMP-dependent protein kinase as opposite effectors of lymphocyte mitogenesis. Nature (1977) 268:63–64.
   PubMed Web of Science ®Google Scholar
• TAGLIAFERRI P, CLAIR T, DEBORTOLI ME, CHO-CHUNG YS: Two classes of cAMP analogs synergistically inhibit p21 ras protein synthesis and phenotypic transforma-tion of NIH/3T3 cells transfected with Ha-MuSV DNA. Biochem. Biophys. Res. Commun. (1985) 130:1193–1200.
   PubMed Web of Science ®Google Scholar
• TAGLIAFERRI P, KATSAROS D, CLAIR T, NECKERS L, ROB-INS RK, CHO-CHUNG YS: Reverse transformation of Harvey murine sarcoma virus-transformed NIH/3T3 cells by site-selective cyclic AMP analogs. J. Biol. Chem. (1988) 263:409–416.
   PubMed Web of Science ®Google Scholar
• CLAIR T, ALLY S, TAGLIAFERRI P, ROBINS RK, CHO-CHUNGYS: Site-selective cAMP analogs induce nuclear translo-cation of the Ms cAMP receptor protein in Ha-MuSV-transformed N111/3T3 cells. FEBS Lett. (1987) 224:337–384.
   Google Scholar
• CIARDEELLO F, TORTORA G, KIM N, CLAIR T, ALLY S,SALOMON DS, CHO-CHUNG YS: 8-Chloro-cAMP inhibits transforming growth factora transformation of Waal-mary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon trans-formation. J. Biol. Chem. (1990) 265:1016–1020.
   PubMedGoogle Scholar
• CIARDEELLO F, PEPE S, BIANCO C, BALDASSARRE G, RUGGIERO A, BIANCO C, SELVAM MP, BIANCO AR, TOR-TORA G: Down-regulation of lila subunit of cAMP-de-pendent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. Int. J. Cancer (1993) 53:438–443.
   PubMedGoogle Scholar
• CHO-CHUNG YS, CLAIR T, TAGLIAFERRI P, ALLY S, KAT-SAROS D, TORTORA G, NECKERS L, AVERY TL, CRABTREE GW, ROBINS RK: Basic Science Review: Site-selective cyclic AMP analogs as new biological tools in growth control, differentiation and proto- oncogene regula-fion. Cancer Inv. (1989) 7:161–177.
   PubMed Web of Science ®Google Scholar
• WATSON DMS, HAWKINS RA, BUNDRFI) NJ, STEWART HJ, MILLER WR: Tumor cyclic AMP binding proteins and endocrine responsiveness in patients with inoperable breast cancer. Br. J. Cancer (1987) 56:141–142.
   PubMedGoogle Scholar
• BRADBURY AW, MILLER WE, CARTER DC: Cyclic adeno-sine 3',5'-monophosphate binding proteins in human colorectal cancer and mucosa. Br.J. Cancer(1991) 63:201–204.
   PubMedGoogle Scholar
• WEBER W, SCHWOCH G, SCHRODER H, HILZ H: Analysis of cAMP-dependent protein kinases by bnmunotitra-don: multiple forms-multiple functions? Cold Spring Harb. Conf. Cell Prolif (1981) 8:125–140.
   Google Scholar
• ICATSAROS D, TORTORA G, TAGLIAFERRI P, CLAIR T, ALLY S, NECKERS L, ROBINS RK, CHO-CHUNG YS: Site-selective cyclic AMP analogs provide a new approach in the control of cancell growth. FE13S Lett. (1987) 223:97–103.
   Google Scholar
• TAGLIAFERRI P, ICATSAROS D, CLAIR T, ALLY S, TORTORA G, NECICERS L, RUBALCAVA B, PARANDOOSH A, CHANG YA, REVANKER GR, CRABTREE GW, ROBINS RK, CHO-CHUNG YS: Synergistic inhibition of growth of breast and colon human cancer cell lines by site-selective cyclic AMP analogs. Cancer Res. (1988) 48:1642–1650.
   PubMed Web of Science ®Google Scholar
• TORTORA G, TAGLIAFERRI P, CLAIR T, COLAMONICI O, NECICERS LM, ROBINS RK, CHO-CHUNG YS: Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelo-cytic, chronic myelocytic, and acute lymphocytic hu-man leukemia cell lines. Blood (1988) 71:230–233.
   PubMed Web of Science ®Google Scholar
• ALLY S, CLAIR T, KATSAROS D, TORTORA G, YOKOZAKI H, FINCH RA, AVERY TL, CHO-CHUNG YS: Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-C1-cyclic adenosine monophosphate. Cancer Res. (1989) 49:5650–5655.
   PubMed Web of Science ®Google Scholar
• ALLY S, TORTORA G, CLAIR T, GRIECO D, MERLO G, KATASAROS D, OGMED D, DSKELAND SO, JAHNSEN T, CHO-CHUNG YS: Selective modulation of protein kinase isozymes by the site- selective analog 8-chloroadenos-Inc 3',5'-cyclic monophosphate provides a biological means for control of human colon cancer cell growth. Proc. Natl. Acad. Sci. USA (1988) 85:6319–6322.
   PubMed Web of Science ®Google Scholar
• CHO-CHUNG YS, CLAIR T, TORTORA G, YOKOZAKI H: Role of site-selective cAMP analogs in the control and reversal of malignancy. Pharmacol. Ther. (1991) 50:133. Thorough review.
   Google Scholar
• CHO-CHUNG YS, CLAIR T, TORTORA G, YOKOZAKI H, PEPE S: Suppression of malignancy targeting the intra-cellular signal transducing proteins of cAMP: The use of site-selective cAMP analogs, antisense strategy, and gene transfer. Life Sci. (1991) 48:1123–1132.
   PubMedGoogle Scholar
• ROHLFF C, CLAIR T, CHO-CHUNG YS: 8-C1-cAMP induces truncation and down-regulation of the RI0 subunit and upreguktion of the RHF, subunit of cAMP-dependent protein kinase leading to type II holoenzyme-depend-cut growth inhibition and differentiation of HL-60 leukemia cells. J. Biol. Chem. (1993) 268:5774–5782.
   PubMed Web of Science ®Google Scholar
• TORTORA G, YOKOZAKI H, PEPE S, CLAIR T, CHO-CHU-NG YS: Differentiation of 111,60 leukemia by type Iregulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA (1991) 88:2011–2015.
   PubMed Web of Science ®Google Scholar
• YOKOZAKI H, BUDILLON A, TORTORA G, MEISSNER S, BEUACAGE SL, MIKI K, CHO-CHUNG YS: An antisense oligodeoxynucleoticle that depletes RI0 subunit of cyclic AMP-dependent protein kinase induces growth inhibi-tion in human can cells. CancerRes. (1993) 53:868–872.
   Google Scholar
• ROTHENBERG M, JOHNSON G, LAUGHLIN C, GREEN I, CRADDOCK J, SARVER N, COHEN JS: Commentary: Oli-godeoxynucleotkles as anti-sense inhibitors of gene expression: Therapeutic implications. J. Natl. Cancer Inst. (1989) 81:1539–1544.
   PubMedGoogle Scholar
• CHO-CHUNG YS, NESTEROVA MV, SEVERIN ES, VINOGRA-DOV SV: Chemical modification enhances the inhibi-tory effect of regulatory subunit antisense oLigodeoxynucleotick of cAMP- dependent protein ki-nase type I on cell proliferation. Biochem. Int. (1991) 25:767–773.
   PubMedGoogle Scholar
• HOFFMAN F, BECHTEL PJ, ICREBS EG: Concentrations ofcyclic AMP-dependent protein kinase subunits in vari-ous tissues. J. Biol. Chem. (1977) 252:1441–1447.
   PubMedGoogle Scholar
• TORTORA G, CLAIR T, CHO CHUNG YS: An antisense oligodeoxynucleotide targeted against the type RBI; regula-tory subunit tuRNA of protein kinase inhibits cAMP-in-duced differentiation in 111,60 leukemia cells without affecting phorbol ester effects. Proc. Natl. Acad. Sci. USA (1990) 87:705–708.
   PubMed Web of Science ®Google Scholar
• TORTORA G, CLAIR T, ICATSAROS D, ALLY S, COIAMONICI0, NECICERS LM, TAGLIAFERRI P, JAHNSEN T, ROBINS RK, CHO-CHUNG YS: Induction of megakaryocytic differen-tiation and modulation of protein kinase gene expres-sion by site-selective cAMP analogs in K-562 human leukemic cells. Proc. Natl. Acad. Sci. USA (1989) 86:2849–2852.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ DA, RUBIN CS: Identification and differentialexpression of two forms of regulatory subunits (RU) of cAMP-dependent protein kinase II in Friend erythroleukemic cells. J. Biol. Chem. (1985) 260:6296–6303.
   PubMedGoogle Scholar
• OTTEN AD, MCKNIGHT GS: Overexpression of the typeII regulator subunit of the cAMP-dependent protein kinase eliminates the type I holoenzyvae in mouse cells. J. Biol. Chem. (1989) 264:20255–20260.
   PubMed Web of Science ®Google Scholar
• OTTEN AD, PARENTEAU LA, DSKELAND S, MCKNIGHT GS:Hormonal activation of gene transcription in ras-trans-formed N1113T3 cells overexpressing RH. and R110 subunits of the cAMP- dependent protein ldnase. J. Biol. Chem. (1991) 266:23074–23082.
   Google Scholar
• CLAIR T, YOKOZAKI H, TORTORA G, MEISSNER S, BEU-CAGE SL, CHO-CHUNG YS: An antisense ollgodeoxynu-cleotide targeted against the type I regulatory subunit (RIO mRNA of cAMP-dependent protein kinase (PICA) inhibits the growth of IS-174T human colon carcinoma In athymic mice. Proc. AACR (1991) 32:277.
   Google Scholar
• CAZENAVE C, LOREAU N, THUONG NT, TOULME JJ, HÉLÈNE C: Enzymatic amplification of translation inhi-bition of rabbit fi-globin mRNA mediated by anti-mes-senger oligodeoxynucleotides covalently linked to intercalating agents. Nucl. Acids Res. (1987) 15(12): 4714–4736.
   Google Scholar
• SHUTTLEWORTH J, COLMAN A: Antisense oligonu-ckotide-directed cleavage of mRNA in Xenopus oocytes and eggs. EMBOJ. (1988) 7(2):427–434.
   PubMed Web of Science ®Google Scholar
• SHUTTLEWORTH J, MATTHEWS G, DALE L, BAKER C, COLMAN A: Antisense oligodeoxyribonucleotkle-di-rected cleavage of maternal mRNA in Xenopus oocytes and embryos. Gene (1988) 72:267–275.
   PubMed Web of Science ®Google Scholar
• SMITH RC, BEMENT WM, DERSCH MA, DWORKIN-RASTLE, DWORKIN MB, CAPCO DG: Nonspecific effects of oligodeoxynucleotides injection In Xenopus oocytes: a reevaluation of previous D7 mRNA ablation experi-ments. Development (1990) 110:769–779.
   PubMedGoogle Scholar
• STOREY A, OATES D, BANKS L, CRAWFORD L, CROOK T: Anti-sense phophorothioate oligonuckoticies have both specific and non-specific effects on cells contain-ing human papillomavirus type 16. Nucl. Acids Res. (1991) 19(15):4109–4114.
   PubMedGoogle Scholar
• HELENE C, TOLTLME B: Control of gene expression by ollgodeoxynucleotides covakntly linked to intercalat-ing agents and nucleic acid-cleaving reagents. In: O/i- gonucleotides: Antisense inhibitors of gene expression (1989). Cohen JS, (Ed), CRC Press, Boca Raton, FL pp. 137–172.
   Google Scholar
• GELES RV, TEDD DM: Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodi-ester/phosphodiester structures. Nucl. Acids Res. (1992) 20(4):763–770.
   PubMedGoogle Scholar
• STEIN CA, SUBASINGHE C, SHINOZUKA K, COHEN JS: Physiochemical properties of phosphorothioate oli-godeoxynucleotides. Nucl. Acids. Res. (1988) 16(8):3209–3221.
   PubMed Web of Science ®Google Scholar
• STEIN CA, COHEN JS: Phosphorothioate oligodeozynu-cleotide analogues. In: Oligonucleotides: Antisense inhibi-tors of gene expression (1989). Cohen JS, (Ed), CRC Press, Boca Raton, FL pp. 97–117.
   Google Scholar
• FURDON PJ, DOMINSKI Z, KOLE R: RNase H cleavage of RNA hybridized to oligonucleotides containing methyl-phosphonate, phosphorothioate and phosphodiester bonds. Nucl. Acids Res. (1989) 17(22):9193–9204.
   PubMed Web of Science ®Google Scholar
• HELENE C: Rational design of sequence-specific once- gene inhibitors based on antisense and antigene oli-gonucleotides. Eur. J. Cancer (1991) 27:1466–1471.
   PubMed Web of Science ®Google Scholar
• BLAKE KR, MURAKAMI A, SPITZ SA, GLAVE SA, REDDY MP, TS'0 POP, MILLER PS: Hybridization arrest of globin synthesis in rabbit reticulocyte lysates and cells by oligodeoxyribonucleoside methylphosphonates. Bio-chemistry (1985) 24:6139–6145.
   Google Scholar
• ECKSTEIN F: Nucleoside phosphorothioates. Ann. Rev. Biochem. (1985) 54:367–402.
   PubMed Web of Science ®Google Scholar
• WALDER RY, WALDER JA: Role of RNase H in hybrid-arrested translation by antisense oligonucleotkles. Proc. Natl. Acad. Sci. USA (1988) 85:5011–5015.
   PubMed Web of Science ®Google Scholar
• AKHTAR S, KOLE R, JULIANO RL: Stability of antisense DNA oligocleoxynucleotkle analogs in cellular extracts and sera. Life Sci (1991) 49:1793–1801.
   PubMed Web of Science ®Google Scholar
• CHENN TL, MILLER PS, TS'0 POP, COLVIN OM: Disposition and metabolism of oligodeozynucleotides methyiphos-phonate following a single Lv. injection in mice. Drug Metab. Disposition (1990) 18:815–818.
   PubMedGoogle Scholar
• BIGELOW JC, CHRIN LR, MATHEWS LA, MCCORMACK IF: High-performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotkles In biological fluids. j Cbromatogr. (1990) 533:133–140.
   PubMed Web of Science ®Google Scholar
• IVERSON P: In vivo studies with phosphorothioate oligonucleotides: Pharmacokinetic prologue. Anti-Can-cer Drug Design (1991) 6:531–538.
   PubMedGoogle Scholar
• JAROSZEWSKI JW, COHEN JS: Celtutsar uptake of antis-ense oligodeoxynucleotides. Adv. Drug Delivery Rev. (1991) 6:235–250.
   Web of Science ®Google Scholar
• LEONETTI JP, MECHTI N, DEGOLS G, GAGNOR C, LEBLEU B: Intracellular distribution of microinjected antisense oligonucleotkies. Proc Natl. Acad. Sci. USA (1991) 88:2702–2706.
   PubMed Web of Science ®Google Scholar
• ZON G: Oligonucleotide analogues as potential che- motherapeutic agents. Pharmacol. Res. (1988) 5:539-549. Thorough review.
   Google Scholar
• CALABRETTA B: Inhibition of protooncogene expres-sion by antisense oligodeoxynucleotides: biological and therapeutic implications. Perspectives in Cancer Re-search (1991) 51:4505–4510.
   PubMed Web of Science ®Google Scholar